Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06807281 · ClinicalTrials.gov registry record · Phase 3
A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
A Phase 3 study of Atopic Dermatitis, sponsored by Pfizer.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 500
- Enrollment target
- 20
- Study locations
NCT06807281 is a Phase 3 study of Atopic Dermatitis that is actively recruiting participants, run by Pfizer. The registered enrollment target is 500 participants, below the 606-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (17% lower). The trial reports 20 study locations across 17 states.
The verdict
NCT06807281, a Phase 3 study of Atopic Dermatitis, is actively recruiting participants, sponsored by Pfizer.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 500 participants
- Enrollment target
- 20
- Study locations
Study Summary
This 24-month study will assess the long-term safety and efficacy of liquid abrocitinib oral suspension with or without topical medications in children 2 years of age or older with moderate-to-severe atopic dermatitis. The study will enroll two groups: participants who have completed other abrocitinib studies and participants who have never participated in abrocitinib studies.
Conditions Studied
Interventions
- DRUG Abrocitinib
Study Locations (20)
Other
- Xinhua Hospital Affiliated to Shanghai JiaoTong University School of Medicine - Shanghai
- Fukuoka National Hospital - Fukuoka
- Servicios Hospitalarios de Mexico S.A. DE C.V. - Chihuahua City
California
- Investigational Drug Service - Rady Childrens Hospital-San Diego - San Diego
- University of California, San Diego/ Rady Children's Hospital - San Diego - San Diego
Alabama
- Cahaba Dermatology & Skin Health Center - Birmingham
Arkansas
- Arkansas Research Trials - North Little Rock
Florida
- Solutions Through Advanced Research - Jacksonville
Indiana
- Dawes Fretzin Clinical Research Group, LLC - Indianapolis
South Carolina
- Tribe Clinical Research, LLC - Greenville
North Rhine-Westphalia
- Universitätsklinikum Münster - Münster
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2025-12-02 |
| Est. Completion | 2032-02-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06807281
The ClinicalTrials.gov registry entry for NCT06807281 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 606-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (17% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 1 intervention - of which Abrocitinib is the first listed.
NCT06807281 reports 20 study locations spanning 17 distinct geographic areas - top geographies include Other, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT06807281 about?
NCT06807281 is a clinical study titled "A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema". This 24-month study will assess the long-term safety and efficacy of liquid abrocitinib oral suspension with or without topical medications in children 2 years of age or older with moderate-to-severe atopic dermatitis. The study will enroll two groups: participants who have completed other abrocitin...
What is the current status of trial NCT06807281?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 500 participants. The study started on 2025-12-02. Estimated completion is 2032-02-22.
What conditions does trial NCT06807281 study?
This clinical trial studies the following conditions: Atopic Dermatitis.
What interventions are being tested in trial NCT06807281?
The interventions under investigation include: Abrocitinib (DRUG).
Who is sponsoring clinical trial NCT06807281?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06807281 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Florida, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis
RECRUITING · Phase 3
-
A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
RECRUITING · Phase 3
-
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 3
-
A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis
RECRUITING · Phase 3
-
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
RECRUITING · Phase 3
-
A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.